Future of Hepatocellular Carcinoma Incidence in the United States Forecast Through 2030
about
The impact of the revolution in hepatitis C treatment on hepatocellular carcinoma.Survival and cost-effectiveness of sorafenib therapy in advanced hepatocellular carcinoma: An analysis of the SEER-Medicare database.Prognostic role of noninvasive liver reserve markers in patients with hepatocellular carcinoma undergoing transarterial chemoembolization.Hepatocellular carcinoma: early-stage management challengesHepatitis C-related hepatocellular carcinoma in the era of new generation antivirals.Racial/ethnic disparities in hepatocellular carcinoma treatment and survival in California, 1988-2012.Adiposity across the adult life course and incidence of primary liver cancer: The NIH-AARP cohort.Disparities in liver cancer occurrence in the United States by race/ethnicity and state.Force-dependent breaching of the basement membrane.Incidence of Hepatocellular Carcinoma in All 50 United States, From 2000 Through 2012.Cohort Contributions to Race- and Gender-Specific Trends in the Incidence of Hepatocellular Carcinoma in the USA.MicroRNA-206 Prevents the Pathogenesis of Hepatocellular Carcinoma Via Modulating Expression of cMet and Cdk6.A unified approach for assessing heterogeneity in age-period-cohort model parameters using random effects.Network analyses identify liver-specific targets for treating liver diseases.Risk factors and prevention of hepatocellular carcinoma in the era of precision medicine.Epidemiology of Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma.Thrombosis after liver transplantation for hepatocellular carcinoma.Predictors of intermediate-term survival with destination locoregional therapy of hepatocellular cancer in patients either ineligible or unwilling for liver transplantation.Aflatoxin and viral hepatitis exposures in Guatemala: Molecular biomarkers reveal a unique profile of risk factors in a region of high liver cancer incidence.Critical evaluation of the American Joint Commission on Cancer (AJCC) 8th edition staging system for patients with Hepatocellular Carcinoma (HCC): A Surveillance, Epidemiology, End Results (SEER) analysis.Linking Race, Cancer Outcomes, and Tissue Repair.Body Composition Predicts Survival in Patients with Hepatocellular Carcinoma Treated with Transarterial Chemoembolization.Correlated Poisson models for age-period-cohort analysis.Effect of hospital safety net designation on treatment use and survival in hepatocellular carcinoma.Natural Medicines Used in the Traditional Tibetan Medical System for the Treatment of Liver Diseases.N-Acetylgalactosamine-Targeted Delivery of Dendrimer-Doxorubicin Conjugates Influences Doxorubicin Cytotoxicity and Metabolic Profile in Hepatic Cancer Cells.Deciphering the epidemiology of hepatocellular carcinoma through the passage of time: A study of 1,401 patients across 3 decades.AASLD guidelines for the treatment of hepatocellular carcinomaRacial/ethnic- and county-specific prevalence of chronic hepatitis B and its burden in CaliforniaUpregulation of BUB1B, CCNB1, CDC7, CDC20, and MCM3 in Tumor Tissues Predicted Worse Overall Survival and Disease-Free Survival in Hepatocellular Carcinoma PatientsNonsteroidal anti-inflammatory drugs, especially aspirin, are linked to lower risk and better survival of hepatocellular carcinoma: a meta-analysisCohort contributions to trends in the incidence and mortality of intrahepatic cholangiocarcinomaStereotactic body radiation therapy following transarterial chemoembolization for unresectable hepatocellular carcinomaIs there an optimal staging system or liver reserve model that can predict outcome in hepatocellular carcinoma?
P2860
Q30250096-E8E705EE-2FC5-43DD-BB09-A9A1BB654905Q30275646-2C36CBA2-D75D-45A5-9003-D49411B11928Q33865883-CA31BFE3-EC6B-4B1A-9252-A0BAA1B0DAE1Q33881131-9BB4F1C2-186E-44D8-BB45-A1ADB897123BQ36306768-DE8EB710-1CD4-4DB8-8A41-48BE51059F6DQ37338966-ED80FA5F-1F84-4BC6-9DCB-F6C2A2825B7FQ38730180-F5229718-4D13-43D6-B635-C36947AB4672Q38741005-161D96D4-0093-448A-AD6E-AA99ED10811DQ39056693-436BBD92-CC83-4F6C-8833-69BCD271CA6DQ39151731-2AB07A09-A391-497F-B515-DE0C438FA41DQ40054265-0902C2B0-744C-434A-B520-B505D5A1BA62Q40132515-97154224-B501-4D89-8EF9-AB857C8F41A6Q40169656-54AC0C22-42A3-40B0-9F20-0628959F18B2Q41526807-13AEEB6D-496C-45EF-8F0D-0ABB23502E73Q41921861-BCC7DA2C-B043-4040-8698-D5C789FD4793Q41991379-9F4991C5-9E63-4248-A981-6FB051591623Q43026378-C7809E37-4C14-48AA-A5A2-9B4B1B776CA1Q44749754-0B089C46-9E4D-4054-A886-E2FE1CD9F534Q47109489-44357D21-73F1-43CE-9798-97F7E97C66A0Q47614432-3CB29922-3C49-4535-890A-F51414762D88Q47839645-53F446DD-466C-4417-961F-42EC3CE9D5DDQ47860297-C9AEDE50-E335-418F-ABEC-42F96D31D3D3Q47860583-5C5B8548-F629-4C2E-86C5-F314A54F3B65Q48124236-89FC62CB-5FC6-43FF-8869-F9AB54D375E2Q49481817-8F735CD3-819B-4904-A03D-D1C726944A2EQ51045603-E038EDB1-7E64-4AA7-9A54-B313E2ED7BD4Q55360535-C51A16CD-D43D-496C-BD92-CF4FDFCCC9B4Q56172239-534B80A9-CB52-4716-B0F3-C31F8B97039BQ57144438-9EBB9D55-8C78-4784-A6FB-CA17DDD63E9FQ58603880-20F1EBB8-CA1C-423B-B19D-D2C349A64DC5Q58777735-D5CDF61D-B824-49C2-AEC0-22EA19B87F71Q58804371-C3685918-C8F1-4C5B-89E0-482EE1B1E0C1Q58806078-9763A348-FECC-43CB-9EE5-53CFB563BB94Q58806088-B557E763-66C7-4CAF-BF44-F8D0C8318699
P2860
Future of Hepatocellular Carcinoma Incidence in the United States Forecast Through 2030
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 04 April 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Future of Hepatocellular Carcinoma Incidence in the United States Forecast Through 2030
@en
Future of Hepatocellular Carcinoma Incidence in the United States Forecast Through 2030.
@nl
type
label
Future of Hepatocellular Carcinoma Incidence in the United States Forecast Through 2030
@en
Future of Hepatocellular Carcinoma Incidence in the United States Forecast Through 2030.
@nl
prefLabel
Future of Hepatocellular Carcinoma Incidence in the United States Forecast Through 2030
@en
Future of Hepatocellular Carcinoma Incidence in the United States Forecast Through 2030.
@nl
P2093
P2860
P356
P1476
Future of Hepatocellular Carcinoma Incidence in the United States Forecast Through 2030
@en
P2093
Jessica L Petrick
Katherine A McGlynn
Sean F Altekruse
P2860
P304
P356
10.1200/JCO.2015.64.7412
P407
P577
2016-04-04T00:00:00Z